Tradestie Institutional Equity Comparison Engine

ABUS vs BEAG โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABUS Overall Edge

ABUS Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Arbutus Biopharma Corporation Common Stock (ABUS) driven by superior Valuation, Growth & Margin, Options & Structure while BEAG counters with relative strength in Momentum & Technical. Fundamentally, ABUS trades at 10.2x Forward P/E with 80.1% operating margin (-43.5% YoY revenue) versus BEAG at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ABUS sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro) against BEAG sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner ABUS
ABUS 10.2x vs BEAG N/M Fwd P/E
Growth & Margin Winner ABUS
Op Margin 80.1% vs 0.0% ยท YoY -43.5% vs +0.0%
Momentum & Technical Winner BEAG
1Y -5.8% vs -2.4% ยท 52W Pos 27% vs 47%
Options & Structure Winner ABUS
CONSOLIDATION (18th %ile IV) vs UNCLASSIFIED (N/A IV)
ABUS NASDAQ
Arbutus Biopharma Corporation Common Stock
Pharmaceutical Preparations
$4.02
-1.23% 1D
Market Cap $623.9M
1M Return -4.51%
1Y Return -5.85%
Forward P/E 10.2x
Unified AI Score
43.4 / 100 HOLD
Tech 28.0 Fund 48.0 Flow 68.0 Mom 53.7
BEAG NASDAQ
Bold Eagle Acquisition Corp. Class A Ordinary Shares
Blank Checks
$10.62
+0.0% 1D
Market Cap $169.1M
1M Return +1.05%
1Y Return -2.39%
Forward P/E N/M
Unified AI Score
52.7 / 100 HOLD
Tech 54.0 Fund 52.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ABUS -5.85% BEAG -2.39% Spread: +6.8 pp (BEAG Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ABUS TTM Op. Margin: 80.1% BEAG TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABUS vs BEAG. Trailing 12-month operating profitability (ABUS 80.1% vs BEAG 0.0%) and valuation multiples (ABUS 10.2x vs BEAG N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ABUS (6) vs BEAG (4)
Institutional Metric ABUS BEAG Criterion Row Winner
Market Capitalization Scale $623.9M $169.1M Larger Scale ABUS
Trailing P/E Ratio Valuation 3.6x 59.0x Lower Multiple ABUS
Forward P/E Ratio Valuation 10.2x N/M Lower Multiple ABUS
Revenue Growth (YoY) Growth -43.5% +0.0% Higher Growth BEAG
Operating Margin (TTM) Profitability 80.1% 0.0% Higher Margin ABUS
Net Profit Margin Profitability 121.2% 0.0% Higher Margin ABUS
Return on Equity (ROE) Capital Efficiency 269.6% 0.0% Higher ROE ABUS
52-Week Range Position Momentum 27% ($4โ€“$5) 47% ($10โ€“$11) Stronger Trend BEAG
Beta / 30D Volatility Risk Regime 1.04ฮฒ ยท 48% Vol -0.01ฮฒ ยท 8% Vol Lower Realized Risk BEAG
Unified Institutional Score Composite Signal 43.4 / 100 (HOLD) 52.7 / 100 (HOLD) Higher Composite BEAG

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ABUS vs BEAG Buy Guide
ABUS CONSOLIDATION
96d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 18th %ile
IV Regime Compressed (<25th %ile)
Live ABUS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BEAG UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BEAG Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ABUS nor BEAG registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.